Global scientific partner of choice to accelerate biomedical research

For more than 75 years, Charles River has delivered solutions to accelerate the development of novel drugs and medical devices for the people and patients who need them. We have built upon our original core competency of research model technologies to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, and a suite of products and services to support our clients’ manufacturing activities. Our products and services are provided through three business segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing. With an expansive end-to-end portfolio, global capacity, and proven scientific expertise, our integrated approach allows clients to enhance their productivity and effectiveness at every point along the drug discovery and development continuum, while lowering costs and increasing speed to market.

At Charles River, we are passionate about our role in transforming the drug development process and delivering innovative, safe, and effective treatments to patients, faster. We are proud to have worked on more than 80% of the FDA drug approvals over the last three years. Our mission, our excellent science, and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

Meeting with Management 2023

Agenda – September 21, 2023 8:30am

Opening Remarks
Todd Spencer, Corporate Vice President, Investor Relations
Video On Demand Presentation
Strategic Overview
James Foster, Chairman, President & CEO
Video On Demand Presentation
Financial Overview
Flavia Pease, Corporate Executive Vice President & CFO
Video On Demand Presentation
ESG & Digital Transformation
Birgit Girshick, Corporate Executive Vice President & COO
Video On Demand Presentation
Discovery & Safety Assessment
Shannon Parisotto, Corporate Executive Vice President, Global Discovery & Safety Assessment
Video On Demand Presentation
Manufacturing Solutions
Biologics Solutions (including C&GT CDMO)
Kerstin Dolph, Corporate Senior Vice President, Global Biologics
Video On Demand Presentation

Microbial Solutions
Greg Marshall, Corporate Vice President, Microbial Solutions
Video On Demand Presentation
Research Models & Services
Dr. Colin Dunn, Corporate Senior Vice President, Global Research Models & Services
Video On Demand Presentation
Questions & Answers
Closing Remarks
James Foster
Blue vials



2022 Fiscal Year


Worked on more than


of the novel drugs approved by the FDA
over the last 3 years (2020-2022)


Revenue growth
(2018-2022 CAGR)


Non-GAAP EPS growth
(2018-2022 CAGR)

5-year Compound Annual Growth Rates. See for reconciliations of Non-GAAP to GAAP results.


Annual Revenue


Reported Revenue Growth


Organic Revenue Growth

See for reconciliations of Non-GAAP to GAAP results.




7.8% increase from fiscal 2021

See for reconciliations of Non-GAAP to GAAP results.


5-Year Annualized Shareholder Return
since 12/31/2018


10-Year Annualized Shareholder Return
since 12/31/2013